FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma
The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.Medscape Medical News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer & Oncology | Filgrastim | Hematology | Myeloma | Neulasta | Neupogen | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants